论文部分内容阅读
有相当一部分肿瘤可以通过提高化疗药物的剂量来提高治疗效果.然而,化疗强度的提高对机体造血-免疫系统的损伤也加重,造血-免疫功能的损伤会招致反复感染和残存瘤细胞的扩散,反而造成不利.本研究意在建立一种能加快高剂量化疗后造血.免疫功能恢复的方法,结果表明:有序的应用GM-CSF、IL-2、抗肿瘤-抗T细胞双功能抗体建立了培养人造血-免疫祖细胞的培养体系,经过3天的培养GM-CSF扩增了5.8倍,对癌细胞的特异性杀伤提高了3.4～5.7倍.将培养后的造血-免疫祖细胞回输给接受了亚去髓化疗剂量的病人(n=19),同时应用G-CSF.化疗方案:乳腺癌、鼻咽癌:5-FU 7500mg/M~2、CF 1200mg/M~2、VP 900mg/M~2、cDDP 150mg/M~2、TAM 500mg/M~2.肺癌:CTX3600mg/M~2、ADM 150mg/M~2、VP16 900mg/M~2、cDDP150mg/M~2,骨肉瘤:IFO 12000mg/M~2、Mesna 6000mg/M~2、VP16 900mg/M~2、CDDP 150mg/M~2.中性粒细胞绝对数(ANC)维持<100/μl的天数和恢复>500/μl的天数,与未处理干细胞回输组相比,分别缩短了5.9天和5.7天(p<0.05,P<0.05)。用此培养体系培养的造血祖细胞回输对血小板的恢复无影响.抗菌素应用和住空气层流室时间,与未处理干细胞回输组相比,分别减少了5.6天和8.9天(P<0.005,p<0.05)。患者巨噬细胞吞噬功能恢复时间和对卡介
A considerable number of tumors can increase the therapeutic effect by increasing the dose of chemotherapeutic agents. However, the increase in chemotherapeutic intensity also exacerbates the damage to the hematopoietic-immune system of the body. Hematopoietic-immune function damage can lead to recurrent infections and proliferation of residual tumor cells. Instead, it is adversely affected. This study was intended to establish a method that can speed up the recovery of hematopoietic and immune functions after high-dose chemotherapy. The results showed that the use of GM-CSF, IL-2, and anti-tumor-anti-T cell bi-functional antibodies was established in an orderly manner. Cultured human hematopoietic-immunogenated progenitor cells cultured in GM-CSF was expanded 5.8-fold over 3 days, and the specific killing of cancer cells was increased 3.4-5.7-fold. Hematopoietic-immunized progenitor cells were cultured back Lost to patients who received a sub-medullinary chemotherapy dose (n=19), while using G-CSF. Chemotherapy: breast cancer, nasopharyngeal carcinoma: 5-FU 7500mg/M~2, CF 1200mg/M~2, VP 900mg/M~2, cDDP 150mg/M~2, TAM 500mg/M~2. Lung cancer: CTX3600mg/M~2, ADM 150mg/M~2, VP16 900mg/M~2, cDDP150mg/M~2, osteosarcoma : IFO 12000mg/M~2, Mesna 6000mg/M~2, VP16 900mg/M~2, CDDP 150mg/M~2. Days when the absolute number of neutrophils (ANC) maintained <100/[mu]l Recovery> 500 days / μl, cell recycle group compared to untreated dry, shortened by 5.9 days and 5.7 days (p <0.05, P <0.05). Hematopoietic progenitor cells cultured with this culture system had no effect on platelet recovery. Antibiotic application and air laminar chamber time were reduced by 5.6 days and 8.9 days, respectively, compared with untreated stem cell reinfusion group (P<0.005). , p<0.05). Phagocytic function recovery time of macrophages and kasuke